Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 29, 2018 08:00 ET | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals Appoints Seasoned Pharmaceutical Executive Craig Collard to Board of Directors

SANTA MONICA, Calif., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological treatments for...
October 22, 2018 08:00 ET | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals to Participate in Opioid Panel at the BARDA Industry Day

Company’s Chief Scientific Officer to Participate in “New Approaches to Combating Opioids” Panel SANTA MONICA, Calif., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant")...
October 18, 2018 08:00 ET | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals Announces Receipt of National Institutes of Health Grant by Walter Reed Army Institute of Research and SUNY Upstate Medical University for Development of a Heroin Vaccine

SANTA MONICA, Calif., Oct. 18, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological treatments for...
September 28, 2018 16:01 ET | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

SANTA MONICA, Calif., Sept. 28, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug...
September 26, 2018 08:00 ET | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals to Present at the Cantor Global Healthcare Conference

SANTA MONICA, Calif., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug...
September 25, 2018 09:26 ET | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals Announces Pricing of Public Offering of Common Stock

SANTA MONICA, Calif., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug...
September 24, 2018 16:01 ET | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals Announces Proposed Public Offering of Common Stock

SANTA MONICA, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug...
September 20, 2018 16:05 ET | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals Announces Contract with Biomedical Advanced Research and Development Authority for Up to $4.6 Million to Accelerate Development of OPNT003, Nasal Nalmefene, for Treatment of Opioid Overdose

SANTA MONICA, Calif., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug...
September 10, 2018 08:00 ET | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals, Inc. and Consort Medical plc Announce Manufacturing Agreement for OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose

SANTA MONICA, Calif., and HEMEL HEMPSTEAD, United Kingdom, Sept. 10, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing...
September 04, 2018 08:00 ET | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals Announces Final Patient Enrolled in Phase 2 Clinical Trial Evaluating OPTN001 in Bulimia Nervosa

Top-line Results Expected in First Quarter of 2019 SANTA MONICA, Calif., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical...